BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31120780)

  • 21. Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma.
    Ricard F; Cimarelli S; Deshayes E; Mognetti T; Thiesse P; Giammarile F
    Clin Nucl Med; 2011 Aug; 36(8):672-7. PubMed ID: 21716019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary Pancreatic Yolk Sac Tumor Presenting as Diffusely Enlarged Pancreas in Initial 18F-FDG PET/CT.
    Sui H; Zhu Z; Li Z; Luo Y
    Clin Nucl Med; 2020 Jun; 45(6):483-486. PubMed ID: 32332317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.
    Kroese TE; Goense L; van Hillegersberg R; de Keizer B; Mook S; Ruurda JP; van Rossum PSN
    Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29917073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDG PET-CT in pediatric Langerhans cell histiocytosis.
    Jessop S; Crudgington D; London K; Kellie S; Howman-Giles R
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28034. PubMed ID: 31599488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
    Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ
    Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
    Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
    J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
    Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
    Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
    Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
    Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer.
    de Jong TL; Koopman D; van der Worp CAJ; Stevens H; Vuijk FA; Vahrmeijer AL; Mieog JSD; de Groot JB; Meijssen MAC; Nieuwenhuijs VB; Lioe-Fee GO; Jager PL; Patijn GA
    Surg Oncol; 2023 Apr; 47():101909. PubMed ID: 36739788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of 18F-FDG PET/CT in restaging and follow-up of patients with GIST.
    Albano D; Mattia B; Giubbini R; Bertagna F
    Abdom Radiol (NY); 2020 Mar; 45(3):644-651. PubMed ID: 31646354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic performance of
    Hotta M; Minamimoto R; Yano H; Gohda Y; Shuno Y
    Cancer Imaging; 2018 Jan; 18(1):4. PubMed ID: 29378659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
    Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
    Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of diffuse large B-cell lymphoma patients with 64-slice multidetector computed tomography versus
    Gómez León N; Vega G; Rodríguez-Vigil Junco B; Suevos Ballesteros C
    Med Clin (Barc); 2018 Oct; 151(7):255-264. PubMed ID: 29705152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.
    Meltzer CC; Luketich JD; Friedman D; Charron M; Strollo D; Meehan M; Urso GK; Dachille MA; Townsend DW
    Clin Nucl Med; 2000 Nov; 25(11):882-7. PubMed ID: 11079584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.
    Lin CY; Lin CL; Kao CH
    Eur J Radiol; 2018 Oct; 107():158-165. PubMed ID: 30292261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.
    Alongi P; Caobelli F; Gentile R; Stefano A; Russo G; Albano D; Baldari S; Gilardi MC; Midiri M
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):224-233. PubMed ID: 27565154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Italian Multicenter Study on Accuracy of
    Cistaro A; Cassalia L; Ferrara C; Quartuccio N; Evangelista L; Bianchi M; Fagioli F; Bisi G; Baldari S; Zanella A; Pillon M; Zucchetta P; Burei M; Sala A; Guerra L; Guglielmo P; Burnelli R; Panareo S; Scalorbi F; Rambaldi I; Piccardo A; Garaventa A; Familiari D; Fornito MC; Lopci E; Mascarin M; Altini C; Ferrari C; Perillo T; Santoro N; Borsatti E; Rubini G
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):e267-e273. PubMed ID: 29739722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.